Versão BETA

Acesso livre
Acesso livre

Covid-19

Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, não houve evidência de diferenças na recuperação após tratamento inicial com imunoglobulina intravenosa (IGIV) isolada, IGIV com glicocorticoides ou glicocorticoides isolados.

18 Jun, 2021 | 10:42h

Treatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

Comentários: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London E Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre


Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, o tratamento inicial com imunoglobulina intravenosa (IGIV) e glicocorticoides foi associado com menor risco de disfunção cardiovascular nova ou persistente em comparação ao tratamento com IGIV isolada.

18 Jun, 2021 | 10:40h

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics


Entrevista em áudio | Potenciais tratamentos para crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19.

18 Jun, 2021 | 10:38h

Audio Interview: Covid-19 in Children – New England Journal of Medicine


Dr. Fauci afirma que os riscos trazidos pela variante Delta acentuam a importância das vacinas.

18 Jun, 2021 | 10:38h

Dr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR


Opinião | Causalidade ou confusão: por que os grupos controle são fundamentais para caracterizar a “long COVID” – “Muitos dos sintomas autorrelatados, como cefaleias intermitentes ou cansaço, são inespecíficos e prevalentes na população geral.”

18 Jun, 2021 | 10:37h

Causation or confounding: why controls are critical for characterizing long COVID – Nature


Estudo mostra que a taxa de reinfecção por COVID-19 é inferior a 1% em pacientes que tiveram doença grave.

18 Jun, 2021 | 10:35h

COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds – University of Missouri-Columbia

Estudo original: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases


Recomendações da ECMM/ISHAM para o manejo clínico da mucormicose associada à COVID-19 em países de baixa e média rendas.

18 Jun, 2021 | 10:34h

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries – Mycosis


Estudo de coorte | Desfechos relacionados a deglutição e voz em pacientes hospitalizados com COVID-19.

18 Jun, 2021 | 10:33h

Swallowing and Voice Outcomes in Patients Hospitalized With COVID-19: An Observational Cohort Study – Archives of Physical Medicine and Rehabilitation

Estudo relacionado: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One


Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.

17 Jun, 2021 | 11:06h

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine

Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

 

Comentário no Twitter:

 


[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.

17 Jun, 2021 | 11:04h

Comunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.